                                                                           Vaccine 31 (2013) 3834–3838



                                                             Contents lists available at SciVerse ScienceDirect


                                                                                 Vaccine
                                                  journal homepage: www.elsevier.com/locate/vaccine




Single-dose varicella vaccine effectiveness in school settings in China夽
Zhe Wang a , Huili Yang b , Keli Li a , Aihua Zhang b , Zijian Feng a,∗∗ , Jane F. Seward c ,
Stephanie R. Bialek c , Chengbin Wang c,∗
a
    Chinese Center for Disease Control and Prevention, Beijing, PR China
b
    Tai’an Center for Disease Control and Prevention, Tai’an, PR China
c
    Centers for Disease Control and Prevention, Atlanta, USA




a r t i c l e            i n f o                            a b s t r a c t

Article history:                                            Background: Varicella vaccine has been available in the private sector in China for a decade as a single-
Received 22 March 2013                                      dose regimen, but varicella vaccine effectiveness (VE) has not been fully examined in school settings
Accepted 25 June 2013                                       yet.
Available online 8 July 2013
                                                            Methods: A matched case–control study was carried out in elementary schools and daycares in Tai’an
                                                            prefecture, Shandong province, China. Clinical diagnosis of varicella and breakthrough disease was used
Keywords:
                                                            for this study. Four controls were randomly selected from classmates; two from classmates of the case
Chickenpox
                                                            and two from another class of the same grade without cases. Vaccination status, date of vaccination,
Vaccine effectiveness
Vaccination coverage
                                                            and vaccine product received if vaccinated were collected from home and clinic immunization records.
                                                            Vaccination status of all students in schools/daycares with varicella cases from home immunization
                                                            records or parental recall was used to calculate vaccination coverage.
                                                            Results: The overall varicella VE was 83.4% (95% conﬁdence interval 71.4–90.3%). Receipt of varicella vac-
                                                            cine ﬁve years or more years before the outbreak was signiﬁcantly associated with breakthrough varicella
                                                            (odds ratio = 4.7, P < 0.001), while age at vaccination (<15 vs. ≥15 months) was not (odds ratio = 1.5,
                                                            P = 0.62). Varicella vaccination coverage was 41% with substantial variation across schools (range of
                                                            0–93.8%).
                                                            Conclusions: Single-dose varicella vaccine is highly effective in school settings. Maintaining limited vacci-
                                                            nation coverage might shift varicella disease burden to older individuals, who are more prone to develop
                                                            severe outcomes if varicella occurs.
                                                                                                                                               Published by Elsevier Ltd.




1. Introduction                                                                            varicella vaccine ﬁrst became available in 1998. Five vaccines
                                                                                           are currently licensed in China for single dose use in persons 12
    Varicella (chickenpox) is a highly contagious disease caused by                        months and older: Varilrix® (GlaxoSmithKline) and four domes-
infection with varicella zoster virus (VZV), and is characterized                          tic vaccines (Baike, Changsheng, Keygen, and Shanghai). The ﬁve
by a generalized pruritic vesicular rash. Although varicella is usu-                       varicella vaccines have similar concentrations of Oka strain VZV:
ally self-limiting and resolves within a week, severe complications,                       >1995 plaque forming unit/dose (0.5 mL) in Varilrix, and >2000
including death, can occur [1].                                                            plaque forming unit/dose (0.5 ml) in the domestic vaccines. The
    Varicella vaccines are now widely available as the most effec-                         ﬁve vaccines have the same temperature requirement (2–8 ◦ C) for
tive measure for prevention and control of varicella. In China,                            cold-chain storage and transportation. Currently, varicella vaccines
                                                                                           are only available for private purchase in China and vaccination
                                                                                           coverage varies substantially by regional level of economic devel-
                                                                                           opment [2–5]. Although their immunogenicity and safety have
 夽 The ﬁndings and conclusions in this report are those of the authors and do not
                                                                                           been assessed previously in randomized clinical trials [6–13], the
necessarily represent the ofﬁcial position of the Centers for Disease Control and
Prevention, U.S. Department of Health and Human Services.
                                                                                           effectiveness of these vaccines in China have not yet been fully
  ∗ Corresponding author at: Centers for Disease Control and Prevention, 1600              examined in school settings, the most likely places for intense
Clifton Road NE, MS A-34, Atlanta, GA 30333, USA. Tel.: +1 404 639 7655;                   varicella exposure as a consequence of decreasing family sizes
fax: +1 404 417 0795.                                                                      in China [14]. A matched case–control study was carried out in
 ∗∗ Corresponding author at: Chinese Center for Disease Control and Prevention, 155
                                                                                           schools and daycares to examine the post-licensure effective-
Changbai Road, Changping District, Beijing 102206, PR China. Tel.: +86 10 58900550;
fax: +86 10 58900551.                                                                      ness of varicella vaccines in school settings in Shandong Province,
     E-mail addresses: fengzj@chinacdc.cn (Z. Feng), cwang1@cdc.gov (C. Wang).             China.

0264-410X/$ – see front matter. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.vaccine.2013.06.075
                                                                Z. Wang et al. / Vaccine 31 (2013) 3834–3838                                               3835

Table 1
Characteristics of the cases and the controls by exposure status in 44 schools, Tai’an prefecture, China, 2010–2011.

                                                            Cases, No. (%) (n = 180)                           Controls, No. (%) (n = 679)             P value

 Sex                                                                                                                                                    0.15
   Male                                                       97 (53.9)                                        328 (48.31)
   Female                                                     83 (46.1)                                        351 (51.69)
 Age in years: mean (SD)                                       7.4 (2.2)                                         7.3 (2.1)                              0.66
 Having any underlying disease                                                                                                                          1.0
   Yes                                                        1 (0. 6)                                           5 (0.74)
   No                                                       179 (99.4)                                         674 (99.26)
 Type of school                                                                                                                                         0.33
   Elementary school                                        118 (65.6)                                         471 (69.37)
   Daycare                                                   62 (34.4)                                         208 (30.63)
 Varicella vaccination status                                                                                                                          <0.001
   Vaccinated                                                18 (10.0)                                         232 (34.17)
   Unvaccinated                                             162 (90.0)                                         447 (65.83)
 Varicella vaccine producta ,b                                                                                                                          0.30
   Baike                                                       3 (16.7)                                         80 (34.637)
   Changsheng                                                 12 (66.6)                                        123 (53.25)
   GlaxoSmithKline                                             0 (0.0)                                           1 (0.43)
   Keygen                                                      1 (5.6)                                          15 (6.49)
   Shanghai                                                    2 (11.1)                                         12 (5.19)
 Age at vaccinationa                                                                                                                                    0.62
   <15 months                                                  3 (16.7)                                         37 (92.50)
   ≥15 months                                                 15 (83.3)                                        195 (92.86)
 Year since varicella vaccination:
   Mean (SD)a                                                  4.1 (2.3)                                         2.9 (2.0)                              0.01
  a
   Single-dose varicella vaccine recipients only.
 b
   One control with missing information on varicella vaccine product received.


2. Methods                                                                               vaccine coverage in the schools and daycare centers under study,
                                                                                         the vaccination status and prior varicella history were collected
2.1. Study population                                                                    from immunization records at home or parental recall and vacci-
                                                                                         nation coverage was calculated after the outbreak was over and
   The China Center for Disease Control and Prevention (CDC)                             excluded those with prior disease history.
and Tai’an CDC conducted a case–control study in schools and
daycare centers in ﬁve counties of Tai’an prefecture, Shandong                           2.3. Statistical analyses
province, from 3/2010 to 6/2011. A case of varicella was deﬁned
as an acute generalized maculopapulovesicular rash without other                            We deﬁned varicella VE as [1 − odds ratio (OR)] × 100%, where
apparent cause [15]. Breakthrough varicella was deﬁned as a case                         OR was calculated from conditional logistic regression for the
that developed >42 days after vaccination [15]. Although vari-                           matched case–control study. Vaccine product-speciﬁc VEs could
cella was not a notiﬁable disease in Tai’an prefecture during this                       only be calculated for the Baike and Changsheng vaccines due to
period, 248 elementary schools and daycare centers in ﬁve counties                       the small number of participants who had received the other vac-
of Tai’an prefecture agreed to report varicella cases to the local                       cine products. We used previously described methods to assess VE
department of health, whose staff enrolled eligible case-patients                        changes with time since vaccination [16]. For pairs in which either
and controls and interviewed parents/guardians. Informed consent                         or both the case and the controls had received varicella vaccine, we
for study participation was obtained from parents/guardians. For                         deﬁned the time since vaccination as the time interval between the
each enrolled case-patient from an elementary school, two class-                         date(s) of vaccination and the rash onset date of the matched case.
mates sitting directly around the case were randomly selected, and                       For assessing vaccination status of controls, we used the date of rash
another two students from a class of same grade without any vari-                        onset in the case as the reference date. Thus, controls who received
cella cases were also randomly selected as controls. Each control                        varicella vaccine after the disease onset date of the matched case
group was analyzed separately with the cases to calculate vaccine                        were deﬁned as unvaccinated. We performed all analyses with SAS
effectiveness and ﬁnding no difference, the controls were grouped                        version 9.2 (SAS Inc., Cary, NC).
together. For each case from a daycare center, two controls were                            China CDC Ethics Committee reviewed and approved this pro-
selected from the case-patient’s classroom and another two con-                          tocol.
trols were randomly selected from daycare attendees of the same
age from a classroom without cases.
                                                                                         3. Results

2.2. Data collection                                                                     3.1. Characteristics of the study participants

    Parents/guardians of the participants were interviewed using a                          There were a total of 180 cases reported from 44 schools and
standard questionnaire to collect information on sociodemograph-                         day cares and 679 controls enrolled. Half (434, 50.5%) of the 859
ics, underlying diseases, prior varicella history, and recent possible                   participants were female. The majority of participants were ele-
VZV exposure. Case and control candidates with prior varicella his-                      mentary school students (589, 68.6%) with a mean age of 7.3 years
tory were excluded. For enrolled cases and controls, vaccination                         (range: 1.3–12.4). Five participants reported having underlying
status, date of vaccination, and vaccine product received if vacci-                      medical conditions of asthma and eczema. More than half of the
nated were collected from immunization records at home or in the                         cases (97/180) reported a VZV exposure, 93 (95.9%) of which were
immunization clinics. Date of rash onset and prior varicella his-                        at school. Of the 250 (29.1%) vaccinated cases and controls, 135
tory were collected from parents or clinic records. For evaluation of                    (54.0%) received Changsheng vaccine and 83 (33.2%) received Baike
3836                                                              Z. Wang et al. / Vaccine 31 (2013) 3834–3838

Table 2
Varicella vaccine effectiveness in a matched case–control study in elementary schools and daycares, Tai’an prefecture, China, 2010–2011.

                               Cases, No. (%) (n = 180)           Controls, No. (%) (n = 679)           Vaccine effectiveness (95% conﬁdence interval)a        P value

 Overall VE
   Vaccinated                 18 (10.0)                           232 (34.2)                            83.4 (71.4–90.3)                                       <0.001
   Unvaccinated             162 (90.0)                            447 (65.8)                            Reference
 VE by age at vaccination
   <15 months                  3 (1.7)                             37 (5.5)                             88.0 (55.3–96.8)                                        0.002
   ≥15 months                 15 (8.3)                            195 (28.7)                            82. (68.8–90.0)                                        <0.001
   Unvaccinated             162 (90.0)                            447 (65.8)                            Reference
 VE by time since vaccination
   <5 years                   10 (5.6)                            194 (28.6)                            88.7 (77.7–94.3)                                       <0.001
   ≥5 years                    8 (4.4)                             38 (5.6)                             47.0 (0–79.2)                                           0.18
   Unvaccinated             162 (90.0)                            447 (65.8)                            Reference
 a
     Vaccine effectiveness (VE) is deﬁned as (1 − odds ratio) × 100.


                                                                                           among those who had received vaccine within ﬁve years (91.4%
                                                                                           vs. 84.5% for Baike and Changsheng, respectively, P = 0.02).

                                                                                           3.3. Varicella vaccination coverage

                                                                                               The overall vaccination coverage among the 19,488 students
                                                                                           from the involved daycares (n = 21) and elementary schools (n = 23)
                                                                                           was 41%, ranging from 0 to 93.8%. The vaccination status of the
                                                                                           majority of vaccinated students (78.5%, 6261/7980) was veriﬁed
                                                                                           with an immunization record from home with the rest based on
                                                                                           parental recall. Elementary school students (n = 12,430) were more
                                                                                           likely to be vaccinated than daycare attendees (n = 7058) (43.6%
                                                                                           vs. 36.4%, P < 0.001) as were children of urban residency (n = 7018)
                                                                                           compared to those from rural areas (n = 12,470) (44.2% vs. 39.1%,
                                                                                           P < 0.001). These differences were largely driven by higher vari-
                                                                                           cella vaccination coverage in urban compared to rural elementary
      Fig. 1. Varicella vaccine effectiveness changes by time since vaccination.
                                                                                           schools (56.9% vs. 39.2%, P < 0.001) (Table 3).

vaccine (Table 1). There were no differences between cases and                             4. Discussion
controls by sex, age, age at vaccination, or type of vaccine product
received. However, cases were less likely to be vaccinated than con-                          Our study showed that single-dose varicella vaccination in China
trols (10.0% vs. 34.5%, P < 0.001), and vaccinated cases had a longer                      was highly effective in preventing varicella in school settings. With
time since vaccination compared to vaccinated controls (3.1 vs. 2.6                        varicella vaccine currently only available in China in the private
years, P = 0.01) (Table 1).                                                                sector, we found moderate varicella vaccination coverage had been
                                                                                           achieved, although there was substantial variation across schools.
3.2. Varicella vaccine effectiveness                                                       Our study is the ﬁrst to examine the effectiveness of two vari-
                                                                                           cella vaccines (Baike and Changsheng) that are produced in China.,
   Overall varicella VE was 83.4% (95% conﬁdence interval:                                 which appear to offer comparable protection to Varilrix® and two
71.4–90.3), with age at vaccination (<15 months vs. ≥15 months)                            other varicella vaccines from China (Shanghai and Changchun, now
having little effect on varicella VE (88% vs. 82.4%, P = 0.59). Varicella                  called Keygen) [13,17–19]. Though our study showed higher vac-
VE did not vary signiﬁcantly during the ﬁrst ﬁve years after vacci-                        cine effectiveness for one of the vaccines, additional studies are
nation, ranging from 81.7% to 94.3% with average of 88.7%, but was                         needed to conﬁrm or refute this ﬁnding. In our study, single-dose
signiﬁcantly lower among those vaccinated more than ﬁve years                              varicella vaccine-induced immunity appears to decrease 5 years
before the outbreak (46.9%, P < 0.001) (Table 2, Fig. 1).                                  after vaccination. This is similar to ﬁndings from an ecological study
   One dose VEs of Baike and Changsheng vaccines were 91.4%                                from the U.S. which reported that vaccine recipients were more
and 77.1% (P < 0.001 for both) respectively, with the difference                           than twice as likely to develop moderate/severe breakthrough
between them statistically signiﬁcant (P = 0.008). This difference                         varicella ≥5 years after vaccination compared to those who had
in VE between the two vaccines remained signiﬁcant even after                              been vaccinated more recently [20]. A retrospective cohort study
addressing the differences in time since vaccination (25.2% among                          in Turkey where varicella vaccine was also available only in pri-
Changsheng recipients had been vaccinated ≥5 years prior to the                            vate section found receipt of vaccination ≥5 years was associated
outbreak vs. 0% among Baike recipients, P < 0.001). The VE for the                         with a more than three-fold likelihood of breakthrough varicella
Baike vaccine was greater than that of the Changsheng vaccine                              compared to more recent vaccination [21]. In contrast, a study of

Table 3
Varicella vaccination coverage in 44 elementary schools and daycares (number of students = 19,488), Tai’an prefecture, China, 2010–2011.

 Residence              Type of school                        Vaccinated students, No. (%) (n = 7980)            Unvaccinated students, No. (%) (n = 11,508)   P value

                        Elementary school (n = 3)             1781 (56.9)                                        1350 (43.1)                                   <0.001
 Urban
                        Daycare (n = 11)                      1323 (34.0)                                        2564 (66.0)

                        Elementary school (n = 20)            3633 (39.1)                                        5666 (60.9)                                    0.90
 Rural
                        Daycare (n = 10)                      1243 (39.2)                                        1928 (60.8)
                                                     Z. Wang et al. / Vaccine 31 (2013) 3834–3838                                                               3837


varicella VE changes after vaccination in Guangzhou China [13]                vaccination status could have led to over- or under-estimation of
did not ﬁnd any statistically signiﬁcant differences in VE during             true vaccine coverage.
the seven years after vaccination. More data are needed to better                 In summary, single-dose varicella vaccine is highly effective in
understand the duration of protection in children after one dose              preventing varicella disease in school settings in China. Optimally,
varicella vaccination, although this is increasingly challenging to           higher varicella vaccination coverage in China should be achieved
investigate as disease circulation declines rapidly in many settings          and maintained during childhood to maximize the beneﬁt of the
after introduction of varicella vaccination.                                  varicella vaccine program in decreasing severe varicella morbidity
    Because the effectiveness of single-dose varicella vaccination is         and mortality for all age groups and to prevent epidemiology shift to
approximately 85% against all varicella regardless of manufacturer            adolescents and adults who are prone to develop severe outcomes
[13,17,19,22], about 15% of vaccinated single-dose recipients may             if varicella occurs.
be incompletely protected against varicella. Over time, this pro-
portion of vaccinated single-dose varicella recipients, which would
                                                                              Acknowledgments
increase along with increases in single-dose vaccine coverage [23],
may become the driving force for school outbreaks [22,24,25].
                                                                                 We highly appreciate the help from the local health depart-
Since two-dose varicella vaccination induces higher immunity and
                                                                              ments, school nurses, and teachers in case ﬁnding and control
protection against varicella [26–28], some counties have imple-
                                                                              enrollment. We also are indebted to the children and their par-
mented a 2-dose vaccine program among children to further reduce
                                                                              ents/guardians for their participation and cooperation.
varicella disease burden and outbreaks [29–31]. Similar to the
                                                                                 Conﬂict of interest statement: The authors have no conﬂicts of
Varivax® and Varilrix® , several varicella vaccines manufactured
                                                                              interest or funding to disclose.
in China, have been shown previously to have higher effective-
ness against moderate/severe varicella than against all varicella
[17,19,22]. Though not examined in this study, because they have              References
been shown to offer similar protection against varicella of any
severity as Varivax® and Varilrix® , it is likely that the two vac-           [1] Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9(3):361–81.
cines from China examined here (Baike and Changsheng) will have               [2] Xu A, Xu Q, Fang X, Bialek S, Wang C. Varicella vaccine uptake in Shandong
                                                                                  province, China. Hum Vaccin Immunother 2012;8(9):1213–7.
similar effect against moderate/severe varicella and in preventing            [3] Huang Y, He Y. Analysis on varicella vaccination among children and
varicella hospitalizations and deaths.                                            its impact factors in Xixiang Community, Baoan District. Prev Med Trib
    Moderate levels of varicella vaccination coverage have been                   2010;16(12):1155–7.
                                                                              [4] Tian Z. Investigation on 8 types of extra EPI vaccines in vaccination clinic
achieved in selected areas in China. Given that varicella vaccine                 in Henan oil-ﬁeld center for disease control and prevention. Mod Prev Med
in China is currently only available in the private sector and                    2008;35(2):327–30.
currently priced at more than 25 US dollars for domestic vari-                [5] Shen H. Analysis on the vaccine coverages in the children from a local commu-
                                                                                  nity. Mod Med J China 2007;9(10):106–7.
cella vaccine and 50 US dollars for imported varicella vaccine,               [6] Lu X, Zhou W, Gu K, Zhu F. Evaluation on safety and immunogenicity of
the coverage levels achieved thus far suggest that varicella vac-                 Changshengkeji frozen-dried live attenuated varicella vaccine. J Southeast Univ
cination is well accepted in China among those who can afford                     2008;27(3):5.
                                                                              [7] Chiu SS, Lau YL. Review of the Varilrix varicella vaccine. Expert Rev Vaccines
it [3–5]. Achieving universal childhood varicella vaccination cov-
                                                                                  2005;4(5):629–43.
erage while varicella vaccine availability is limited to the private          [8] Wang L, Liu Y, Li L, Li Z, Li Y, Ha X, et al. Observation on the immunity efﬁcacy
sectors appears unlikely. Including varicella vaccine in the national             of domestic freeze-dried live attenuated varicella vaccine. South China J Prev
                                                                                  Med 2003;2(29).
or local immunization program could be a durable choice to achieve
                                                                              [9] Wang S, Li C, Li Y, Yuan J, Tao H, Wang Z, et al. Study on safety and immunogenic-
and maintain high vaccine coverage [2]. A potential disadvantage                  ity of lyophilized live attenuated domestic varicella vaccine. Chin J Vaccines
of achieving and maintaining only moderate levels of vaccination                  Immunization 2000;6(6):4.
coverage is a decreased risk of varicella exposure for unvaccinated          [10] Ndumbe PM, Cradock-Watson JE, Heath RB, Levinsky RJ. Live varicella immu-
                                                                                  nization in healthy non-immune nurses. Postgrad Med J 1985;61(Suppl.
individuals during childhood which, over the long term, might                     4):133–5.
cause a shift in the epidemiology of varicella that would result             [11] Kappagoda C, Shaw P, Burgess M, Botham S, Cramer L. Varicella vaccine in non-
in an increase in the numbers of cases among older individuals                    immune household contacts of children with cancer or leukaemia. J Paediatr
                                                                                  Child Health 1999;35(4):341–5.
who are more likely to develop severe outcomes if varicella occurs.          [12] Arvin AM. Varlirix (GlaxoSmithKline). Curr Opin Investig Drugs
For this reason, the World Health Organization recommends high                    2002;3(7):996–9.
(85–90%) and sustained routine vaccination coverage levels as a              [13] Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S. The effectiveness of varicella
                                                                                  vaccine in China. Pediatr Infect Dis J 2010;29(8):690–3.
prerequisite for the introduction of a varicella vaccination program         [14] Jin L, Feng F. Analysis of the epidemic situation of chicken pox from 2005 to
[32]. If fully implemented, in addition to reducing varicella among               2006 in China. Disease Surveill 2007;22(4):251–3.
children, a routine childhood varicella vaccination program has the          [15] Council of State and Territorial Epidemiologists and Position Statement Num-
                                                                                  ber: 09-ID-68. Public Health Reporting and National Notiﬁcation for Varicella.
potential to reduce VZV exposure in infants who are too young to
                                                                             [16] Niccolai LM, Ogden LG, Muehlenbein CE, Dziura JD, Vazquez M, Shapiro ED,
be eligible for vaccination, and adults, as well as those for whom                et al. Methodological issues in design and analysis of a matched case–control
vaccination is contraindicated but who remain at high risk of severe              study of a vaccine’s effectiveness. J Clin Epidemiol 2007;60(11):1127–31.
                                                                             [17] Sheffer R, Segal D, Rahamani S, Dalal I, Linhart Y, Stein M, et al. Effectiveness of
disease.
                                                                                  the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in
    Several limitations should be considered in interpreting our                  clinical practice in Israel. Pediatr Infect Dis J 2005;24(5):434–7.
ﬁndings. We employed a clinical case deﬁnition that did not require          [18] Passwell JH, Hemo B, Levi Y, Ramon R, Friedman N, Lerner-Geva L. Use of a
lab conﬁrmation. Though medical practitioners in the study site                   computerized database to study the effectiveness of an attenuated varicella
                                                                                  vaccine. Pediatr Infect Dis J 2004;23(3):221–6.
were likely experienced in diagnosing varicella, their expertise             [19] Seward JF, Marin M, Vazquez M. Varicella vaccine effectiveness in the US vac-
with recognizing the milder clinical presentations of breakthrough                cination program: a review. J Infect Dis 2008;197(Suppl. 2):S82–9.
varicella is unknown, therefore under-reporting of varicella in vac-         [20] Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al.
                                                                                  Loss of vaccine-induced immunity to varicella over time. N Engl J Med
cinated persons may have occurred. If under-ascertainment of                      2007;356(11):1121–9.
cases in vaccinated children occurred, our VE estimate would an              [21] Kurugol Z, Halicioglu O, Koc F, Koturoglu G, Aksit S. Varicella rates among unvac-
overestimation. The vaccination status was assessed at the end of                 cinated and one-dose vaccinated healthy children in Izmir, Turkey. Int J Infect
                                                                                  Dis 2011;15(7):e475–80.
school outbreaks, therefore the vaccine coverage might be overesti-          [22] Lu L, Suo L, Li J, Zhai L, Zheng Q, Pang X, et al. A varicella outbreak in
mated in that some children counted as vaccinated may have gotten                 a school with high one-dose vaccination coverage, Beijing, China. Vaccine
vaccinated during the outbreaks. Moreover, using parental recall on               2012;30(34):5094–8.
3838                                                             Z. Wang et al. / Vaccine 31 (2013) 3834–3838


[23] Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, et al. Changing      [28] Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J,
     varicella epidemiology in active surveillance sites – United States, 1995–2005.          et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis
     J Infect Dis 2008;197(Suppl. 2):S71–5.                                                   2011;203(3):312–5.
[24] Civen R, Lopez AS, Zhang J, Garcia-Herrera J, Schmid DS, Chaves SS, et al. Vari-    [29] Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: rec-
     cella outbreak epidemiology in an active surveillance site, 1995–2005. J Infect          ommendations of the Advisory Committee on Immunization Practices (ACIP).
     Dis 2008;197(Suppl. 2):S114–9.                                                           MMWR Recomm Rep 2007;56(RR-4):1–40.
[25] Lai CC, Chen SC, Jiang DD. An outbreak of varicella among schoolchildren in         [30] Wiese-Posselt M, Hellenbrand W. Changes to the varicella and pertussis
     Taipei. BMC Public Health 2011;11:226.                                                   immunisation schedule in Germany 2009: background, rationale and imple-
[26] Watson B. Humoral and cell-mediated immune responses in children and                     mentation. Euro Surveill 2010;15(16).
     adults after 1 and 2 doses of varicella vaccine. J Infect Dis 2008;197(Suppl.       [31] Salvadori M. Preventing varicella: recommendations for routine two-dose
     2):S143–6.                                                                               varicella immunization in children. Paediatr Child Health 2011;16(7):
[27] Kuter B, Matthews H, Shineﬁeld H, Black S, Dennehy P, Watson B, et al. Ten year          415–6.
     follow-up of healthy children who received one or two injections of varicella       [32] Varicella vaccines. WHO position paper. Wkly Epidemiol Rec
     vaccine. Pediatr Infect Dis J 2004;23(2):132–7.                                          1998;73(32):241–8.
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.
